Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1491-1500
Published online before print July 3, 2003, doi: 10.1161/01.ATV.0000084827.77945.66
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/9/1491    most recent
01.ATV.0000084827.77945.66v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bates, S. M.
Right arrow Articles by Weitz, J. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bates, S. M.
Right arrow Articles by Weitz, J. I.
Related Collections
Right arrow Anticoagulant mechanisms
Right arrow Arterial thrombosis
Right arrow Deep vein thrombosis
Right arrow Other anticoagulants
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1491.)
© 2003 American Heart Association, Inc.

Brief Reviews

Emerging Anticoagulant Drugs

Shannon M. Bates; Jeffrey I. Weitz

From the Department of Medicine (S.M.B., J.I.W.), McMaster University and Henderson Research Centre (J.I.W.), Hamilton, Ontario, Canada.

Correspondence to Dr Jeffrey I. Weitz, Henderson Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3, Canada. E-mail jweitz{at}thrombosis.hhscr.org

Abstract—The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing.


Key Words: anticoagulant • antithrombotic • venous thromboembolism • arterial thromboembolism • direct thrombin inhibitor




This article has been cited by other articles:


Home page
 LupusHome page
V Pengo
New trends in anticoagulant treatments
Lupus, September 1, 2005; 14(9): 789 - 793.
[Abstract] [PDF]

Home page
 CirculationHome page
S. J. McRae and J. S. Ginsberg
Initial Treatment of Venous Thromboembolism
Circulation, August 31, 2004; 110(9_suppl_1): I-3 - I-9.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. S.V. Elkind and R. L. Sacco
Direct Thrombin Inhibition: A Novel Approach to Stroke Prevention in Patients With Atrial Fibrillation
Stroke, June 1, 2004; 35(6): 1519 - 1522.
[Full Text] [PDF]

Home page
 StrokeHome page
G. J. Hankey, C. J.M. Klijn, and J. W. Eikelboom
Ximelagatran or Warfarin for Stroke Prevention in Patients With Atrial Fibrillation?
Stroke, February 1, 2004; 35(2): 389 - 391.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit
Thrombophilia and New Anticoagulant Drugs
Hematology, January 1, 2004; 2004(1): 424 - 438.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.